Predictive Value of QT Dispersion for Acute Heart Failure after Autologous and Allogeneic Hematopoietic Stem Cell Transplantation

American Journal of Hematology

Volumn 76, Issue 1, 2004, Pages 1-7

  Nakamae, Hirohisa ^a   Hino, Masayuki ^a   Akahori, Mika ^a   Terada, Yoshiki ^a   Yamane, Takahisa ^a   Ohta, Kensuke ^a   Hayashi, Tomoshige ^a   Tsumura, Kei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticancer drugs; Drug toxicity; Electrocardiography; Heart failure; Hematopoietic stem cells; Transplantation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIURETIC AGENT; ETOPOSIDE; MELPHALAN; MITOXANTRONE; RANIMUSTINE;

ACUTE HEART FAILURE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; GRAFT VERSUS HOST REACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOXIA; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; QT DISPERSION; SINUS TACHYCARDIA; STATISTICAL MODEL; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIAC OUTPUT, LOW; ELECTROCARDIOGRAPHY; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2342468821     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20042     Document Type: Article

References (39)

1. Lee CK, Harman GS, Hohl RJ, Gingrich RD. Fetal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant 1996;18:573-577.
2. Santos GW, Sensenbrenner LL, Burke PJ, et al. The use of cyclophosphamide for clinical marrow transplantation. Trans Proc 1972;4:559-564.
3. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986;68:1114-1118.
4. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986;57:2061-2069.
5. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide. Arch Intern Med 1981;141:758-763.
6. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant 2001;28:101-103.
7. Olivieri A, Corvatta L, Montanari M, et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Blood 1998;21:1049-1053.
8. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992;15:739-742.
9. Grimm W, Steder U, Menz V, Hoffmann J, Grote F, Maisch B. Clinical significance of increased QT dispersion in the 12-lead standard ECG for arrhythmia risk prediction in dilated cardiomyopathy. PACE 1996;19:1886-1889.
10. Barr CS, Naas AA, Fenwick M, Struthers A. Enalapril reduces QTc dispersion in mild congestion heart failure secondary to coronary artery disease. Am J Cardiol 1997;79:328-333.
11. Sarubbi B, Orditura M, Ducceschi V, et al. Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 1997;12:262-266.
12. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 1999;245:359-364.
13. Orditura M, Sarubbi B, DeVita F, et al. Prolonged corrected QT. dispersion: early sign of doxorubicin cardiotoxicity? Oncol Rep 1997;4:1047-1050.
14. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high dose cyclophosphamide. Lancet 2000;355:805-806.
15. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-1936.
16. Karpanou EA, Vyssoulis GP, Psichoigios A, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998;136:765-768.
17. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-370.
18. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-1446.
19. Herait P, Poutignat M, Marty M, Bugat R. Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete - the French experience with pirarubicin. Eur J Cancer 1992;28A:1670-1676.
20. Casazza AM, Bertazzori C, Pratesi G, Bellini O, Marco A. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DMD) in mice. Proc Am Assoc Cancer Res 1979;20:16.
21. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981;9:417-422.
22. Lehmann S, Isberg B, Ljungmann P, Paul C. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 2000;26:187-192.
23. Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant 2000;25:885-894.
24. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 1990;5:173-177.
25. Hertenstein B, Stefanic M, Schmeiser M, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. Bone Marrow Transplant 1994;12:998-1004.
26. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in hematopoietic stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001;27:307-310.
27. Bristow MR, Billinghan ME, Mason JW. Clinical spectrum of anthracycline cardiotoxicity. Cancer Treat Rep 1978;12:873-879.
28. Lefrak EA, Pitha J, Rosenhei S, Gottlieb JA. Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;33:302-314.
29. Schwartz RG, McKenzie WB, Alexander S, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: a 7-year experience using serial radionuclide angiography. Am J Med 1987;82:1109-1118.
30. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J 1990;4:3076-3086.
31. Minotti G, Cavaliere AF, Mordente A, et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 1995;4:1595-1605.
32. Auner HW, Tinchon C, Brezinschek RI, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarization indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002;69:1-6.
33. Vanbesien K, Tabocoff J, Rodriquez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate-grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549-555.
34. Appelbaum FR, Deisseroth AB, Graw RG, et al. Prolonged complete remission following high-dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 1978;41:1059-1063.
35. Appelbaum F, Strauchen JA, Graw RG Jr, et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976;1:58-62.
36. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-763.
37. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-4536.
38. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;8: 2817-2824.
39. Nishio M, Nakao S, Endo T, et al. Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure. Bone Marrow Transplant 2001;28:783-785.